Cargando…

Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study

BACKGROUND: Hypersalivation is a major side-effect of clozapine in patients with treatment-resistant schizophrenia. AIMS: We investigated the efficacy of topical anticholinergic formulation sofpironium bromide gel for improving hypersalivation in patients with treatment-resistant schizophrenia recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amano, Yuhei, Mazda, Jun, Amano, Koichi, Ohi, Kazutaka, Shioiri, Toshiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885354/ https://www.ncbi.nlm.nih.gov/pubmed/36636808 http://dx.doi.org/10.1192/bjo.2022.630

Ejemplares similares

Two‐week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis
por: Fujimoto, Tomoko, et al.
Publicado: (2022)

Clozapine: Drowsiness with markedly increased hypersalivation and myoclonus secondary to clozapine toxicity: case report
Publicado: (2021)

A phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis
por: Yokozeki, Hiroo, et al.
Publicado: (2021)

Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series
por: Takeuchi, Ippei, et al.
Publicado: (2015)

A phase III, 52‐week, open‐label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis
por: Fujimoto, Tomoko, et al.
Publicado: (2021)

A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)
por: Livermore, Cecilia, et al.
Publicado: (2022)

Investigating genetic overlaps of the genetic factor differentiating schizophrenia from bipolar disorder with cognitive function and hippocampal volume
por: Ohi, Kazutaka, et al.
Publicado: (2022)

Differences in subcortical brain volumes among patients with schizophrenia and bipolar disorder and healthy controls
por: Ohi, Kazutaka, et al.
Publicado: (2022)

Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): a feasibility study
por: Qurashi, Inti, et al.
Publicado: (2019)

Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study
por: Veerman, S. R. T., et al.
Publicado: (2016)

Cessation of clozapine-induced severe hypersalivation along with improvement of residual persistent auditory hallucinations by tDCS in a patient of chronic schizophrenia - A case report
por: Astha,, et al.
Publicado: (2022)

Causal associations of intelligence with schizophrenia and bipolar disorder: A Mendelian randomization analysis
por: Ohi, Kazutaka, et al.
Publicado: (2021)

A Questionnaire-based Study of the Views of Schizophrenia Patients and Psychiatric Healthcare Professionals in Japan about the Side Effects of Clozapine
por: Takeuchi, Ippei, et al.
Publicado: (2016)

Polygenic Risk Scores Differentiating Schizophrenia From Bipolar Disorder Are Associated With Premorbid Intelligence in Schizophrenia Patients and Healthy Subjects
por: Ohi, Kazutaka, et al.
Publicado: (2021)

Polygenic risk scores for late smoking initiation associated with the risk of schizophrenia
por: Ohi, Kazutaka, et al.
Publicado: (2020)

Polygenetic Risk Scores for Major Psychiatric Disorders Among Schizophrenia Patients, Their First-Degree Relatives, and Healthy Participants
por: Ohi, Kazutaka, et al.
Publicado: (2020)

Differences in Executive Function Among Patients With Schizophrenia, Their Unaffected First-Degree Relatives, and Healthy Participants
por: Kataoka, Yuzuru, et al.
Publicado: (2020)

T173. POLYGENETIC RISK SCORES FOR MAJOR PSYCHIATRIC DISORDERS AMONG SCHIZOPHRENIA PATIENTS, THEIR FIRST-DEGREE RELATIVES AND HEALTHY SUBJECTS
por: Ohi, Kazutaka, et al.
Publicado: (2020)

Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study
por: Qurashi, Inti, et al.
Publicado: (2016)

Sex differences in brainstem structure volumes in patients with schizophrenia
por: Aoyama, Shintaro, et al.
Publicado: (2023)

Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis
por: Jun, Jin‐Sun, et al.
Publicado: (2017)

Mitochondrial genetic variants associated with bipolar disorder and Schizophrenia in a Japanese population
por: Tachi, Ryobu, et al.
Publicado: (2023)

The Treatment of Hypersalivation in Rett Syndrome with Botulinum Toxin: Efficacy and Clinical Implications
por: Bernardo, Pia, et al.
Publicado: (2019)

Hypersalivation and coarse tremors as uncommon side effects of acamprosate: A case report
por: Bhandutia, D., et al.
Publicado: (2021)

Hiccups, Hypersalivation, Hallucinations in Parkinson’s Disease: New Insights, Mechanisms, Pathophysiology, and Management
por: Metta, Vinod, et al.
Publicado: (2023)

Ictal hypersalivation as a prominent symptom in a girl with insulo‐opercular epilepsy
por: Sun, Ke, et al.
Publicado: (2023)

Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder
por: Hebrani, Paria, et al.
Publicado: (2015)

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial
por: Barnes, Thomas R.E., et al.
Publicado: (2018)

Ictal Hypersalivation and Salivary Gland Enlargement in a Patient With Acquired Frontal Lobe Epilepsy
por: Mader, Edward C, et al.
Publicado: (2021)

Suppression of Low-Frequency Gamma Oscillations by Activation of 40-Hz Oscillation
por: Sugiyama, Shunsuke, et al.
Publicado: (2021)

The 40-Hz auditory steady-state response enhanced by beta-band subharmonics
por: Sugiyama, Shunsuke, et al.
Publicado: (2023)

USE OF CLOZAPINE IN CHILDHOOD SCHIZOPHRENIA
por: Srinivasan, T.N., et al.
Publicado: (1997)

Cortical gyrification in schizophrenia: current perspectives
por: Matsuda, Yukihisa, et al.
Publicado: (2018)

Polygenic risk scores for major psychiatric and neurodevelopmental disorders contribute to sleep disturbance in childhood: Adolescent Brain Cognitive Development (ABCD) Study
por: Ohi, Kazutaka, et al.
Publicado: (2021)

Water-filtered infrared-A (wIRA) overcomes swallowing disorders and hypersalivation – a case report
por: Hoffmann, Gerd
Publicado: (2017)

Effectiveness of clozapine in treatment-resistant schizophrenia
por: Raguraman, Janakiraman, et al.
Publicado: (2005)

Clozapine: Improvement of Negative Symptoms of Schizophrenia
por: Khan, Afaque H, et al.
Publicado: (2017)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

Management of patients with Clozapine Resistant Schizophrenia
por: Rajendran*, Nithya Ragavi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gbrjb4uisj3qrff7der76d75gn